MAR-GALANTAMINE ER CAPSULE (EXTENDED RELEASE)

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

GALANTAMINE (GALANTAMINE HYDROBROMIDE)

Disponibbli minn:

MARCAN PHARMACEUTICALS INC

Kodiċi ATC:

N06DA04

INN (Isem Internazzjonali):

GALANTAMINE

Dożaġġ:

24MG

Għamla farmaċewtika:

CAPSULE (EXTENDED RELEASE)

Kompożizzjoni:

GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

30

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0144660005; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2021-05-10

Karatteristiċi tal-prodott

1
PRODUCT MONOGRAPH
PR
MAR-GALANTAMINE ER
galantamine hydrobromide extended release capsules
8 mg, 16 mg, 24 mg galantamine base
Cholinesterase Inhibitor
Marcan Pharmaceuticals Inc.
Date of Revision:
77 Auriga Drive, Unit# 4
January 15, 2018
Ottawa, ON, CANADA
K2E 7Z7
Control No.: 212078
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
.................................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................................
3
CONTRAINDICATIONS
............................................................................................................................
3
WARNINGS AND PRECAUTIONS
..........................................................................................................
3
ADVERSE REACTIONS
............................................................................................................................
7
DRUG INTERACTIONS
...........................................................................................................................
12
DOSAGE AND ADMINISTRATION
......................................................................................................
14
OVERDOSAGE
.........................................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................................
16
STORAGE AND STABILITY
..................................................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................................
20
PART II: SCIENTIFIC INFORMATION
..............................................................................................